Publicaciones en las que colabora con Javier de la Rubia Comos (96)

2024

  1. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide

    Transplantation and Cellular Therapy, Vol. 30, Núm. 5, pp. 538.e1-538.e10

  2. Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide

    Bone Marrow Transplantation

  3. Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience

    Bone Marrow Transplantation, Vol. 59, Núm. 10, pp. 1376-1386

  4. Single-Unit Transfusion Policy in Autologous Hematopoietic Stem Cell Transplantation: Less is Not Worse

    Transfusion Medicine Reviews, Vol. 38, Núm. 4

2023

  1. Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation

    Transplantation and Cellular Therapy, Vol. 29, Núm. 5, pp. 313.e1-313.e10

  2. Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

    Cancers, Vol. 15, Núm. 8

  3. Reduced Incidence of Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Calcineurin-Free Graft-versus-Host Disease Prophylaxis

    Transplantation and Cellular Therapy, Vol. 29, Núm. 10, pp. 610.e1-610.e12

  4. T Cell-Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia

    Transplantation and Cellular Therapy, Vol. 29, Núm. 5, pp. 322.e1-322.e5

  5. Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution

    Journal of Clinical Medicine, Vol. 12, Núm. 10

2022

  1. Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

    Cancers, Vol. 14, Núm. 8

  2. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 9, pp. 1389-1398

2021

  1. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?

    Transplant Infectious Disease, Vol. 23, Núm. 4

2017

  1. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

    Neurological Sciences, Vol. 38, Núm. 7, pp. 1213-1221

2015

  1. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

    Leukemia and Lymphoma, Vol. 56, Núm. 2, pp. 415-419

  2. Neutrofilia

    Manual práctico de hematología clínica (Molins de Rei [Barcelona] : Antares, 2012), pp. 129-132

  3. Púrpura trombótica trombocitopénica y síndrome hemolítico urémico

    Manual práctico de hematología clínica (Molins de Rei [Barcelona] : Antares, 2012), pp. 467-472

  4. Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation

    Blood Transfusion, Vol. 13, Núm. 3, pp. 411-416

2014

  1. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: A single-center experience

    Bone Marrow Transplantation, Vol. 49, Núm. 8, pp. 1084-1088

  2. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

    Annals of Hematology

  3. Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 11, pp. 1744-1750